Follow-up study of patients randomized in The Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering

American Journal of Cardiology

Volumn 86, Issue 3, 2000, Pages 257-262

  Pedersen, Terje R ^a   Wilhelmsen, Lars ^b   Færgeman, Ole ^c   Strandberg, Timo E ^d   Thorgeirsson, Gudmundur ^e   Troedsson, Linda ^f   Kristianson, Johan ^f   Berg, Kåre ^g   Cook, Thomas J ^h   Haghfelt, Torben ⁱ   Kjekshus, John ^a   Miettinen, Tatu ^d   Olsson, Anders G ^j   Pyörälä, Kalevi ^k   Wedel, Hans ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^f MSD Scandinavia   (Sweden)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^j LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^k KUOPIO UNIVERSITY HOSPITAL   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PLACEBO; RESIN; SIMVASTATIN; STATINE DERIVATIVE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEATH CERTIFICATE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0033914187     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00910-3     Document Type: Article

References (13)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
3. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., McFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
4. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
5. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
6. Gould A.L., Rossouw J.E., Santanello N.C., Heyse J.F., Furberg C.D. Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation. 97:1998;946-952.
7. A co-operative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J. 40:1978;1069-1118.
8. Newman T.B., Hulley S.B. Carcinogenicity of lipid-lowering drugs. JAMA. 275:1996;55-60.
9. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., Maenpaa H., Malkonen M., Manttani M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjöblom T. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia (safety of treatment, changes in risk factors, and incidence of coronary heart disease). N Engl J Med. 317:1987;1237-1245.
10. Huttunen J.K., Heinonen O.P., Manninen V., Koskinen O., Hakulines T., Teppo L., Mänttäri M., Frick M.H. The Helsinki Heart Study an 8.5-year safety and mortality follow-up . J Intern Med. 235:1994;31-39.
11. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyörälä K., Miettinen T.A., Christophersen B., Tobert J.A., Musliner T.A., Cook T.J. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
12. Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J. 308:1994;367-372.
13. Pedersen T.R., Berg K., Cook T.J., Færgeman O., Haghfelt T., Kjekshus J., Miettinen T.A., Musliner T.A., Olsson A.G., Pyörälä K., Thorgeirsson G., Tobert J.A., Wedel H., Wilhelmsen L. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 156:1996;2085-2092.